Pavmed
PAVmed Inc. is a medical device company based in New York, specializing in the development and commercialization of innovative medical technologies. Founded in 2014, PAVmed's product pipeline includes a diverse range of devices aimed at addressing various medical conditions. Key offerings include CarpX, a device for treating carpal tunnel syndrome; EsoCheck, a non-invasive tool for detecting esophageal cancer precursors; and PortIO, an implantable vascular access device. The company also develops DisappEAR, an antimicrobial ear tube, alongside other products like NextCath, a self-anchoring catheter, and Caldus, a disposable tissue ablation device. PAVmed aims to advance its technologies with efficiency and speed, leveraging the expertise of its founders, who are experienced medical device entrepreneurs and surgeons.
Oncodisc
Acquisition in 2021
Oncodisc, Inc. is a California-based company that specializes in the development of connected vascular access devices designed for oncology patients. Its flagship product is an implantable vascular access port that not only facilitates medication delivery but also monitors patients' health during high-risk outpatient therapies. The device is equipped with advanced sensors and wireless communication capabilities, allowing for real-time monitoring and early detection of complications. Oncodisc also provides data analytics solutions that alert healthcare providers to patients showing early signs of issues, which can lead to timely interventions and reduced hospitalizations. Additionally, the company offers a Remote Care Platform that includes mobile tools for validated patient-reported outcomes, telehealth services, and enhanced patient engagement. Established in 2018, Oncodisc aims to improve cancer care through innovative technology that fosters personalized treatment and better communication between patients and healthcare providers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.